Highs and Lows of Stem Cell Therapies: Off-The-Shelf Solutions
This report will review the current commercial and regulatory landscape for the stem cell therapies, and assesses the challenges and opportunities for developing autologous and allogenic “off the shelf” solutions to treat a broad range of diseases and injuries.
- An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies
- Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options
- Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs)
- Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers
- Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic “off the shelf” solutions
Dr. Cheryl L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.